DelveInsight’s, “Adenoid Cystic Carcinoma - Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adenoid Cystic Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Adenoid Cystic Carcinoma: Overview
Adenoid cystic carcinoma (AdCC) is a rare form of adenocarcinoma, which is a broad term describing any cancer that begins in glandular tissues. In general, AdCC is found mainly in the head and neck region. It can occasionally occur in other locations in the body, including the breasts or a woman’s uterus. AdCC most commonly occurs in the salivary glands, which consist of clusters of cells that secrete saliva scattered throughout the upper aerodigestive tract. The upper aerodigestive tract includes the organs and tissues of the upper respiratory tract, such as the lips, mouth, tongue, nose, throat, vocal cords, and part of the esophagus and windpipe. Regardless of where it starts, AdCC tends to spread along nerves, known as a perineural invasion, or through the bloodstream. It spreads to the lymph nodes in about 5% to 10% of cases. If it spreads to another part of the body beyond the lymph nodes, it is called metastatic cancer. The most common place of AdCC metastases is the lung. AdCC is known for having long periods of no growth, or indolence, followed by growth spurts. But AdCC can behave aggressively in some people, making the course of the AdCC unpredictable. The initial symptoms of AdCC depend on the location of the tumor. Early lesions of the salivary glands may appear as painless, usually slow-growing masses underneath the normal lining of the mouth or skin of the face. Because there are many salivary glands under the mucosal lining of the mouth, throat, and sinuses, lumps in these locations could be from this type of tumor. Other symptoms may include: A lump on the roof of the mouth, under the tongue, or in the bottom of the mouth, an abnormal area on the lining of the mouth, numbness of the upper jaw, palate, face, or tongue and difficulty swallowing. Doctors use many tests to find, or diagnose, cancer. They also do tests to learn if cancer has spread to another part of the body from where it started. If this happens, it is called metastasis. For example, imaging tests can show if the cancer has spread. Imaging tests show pictures of the inside of the body. Doctors may also do tests to learn which treatments could work best. For most types of cancer, a biopsy is the only sure way for the doctor to know if an area of the body has cancer. In a biopsy, the doctor takes a small sample of tissue for testing in a laboratory. If a biopsy is not possible, the doctor may suggest other tests that will help make a diagnosis.
“Adenoid Cystic Carcinoma- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Adenoid Cystic Carcinoma pipeline landscape is provided which includes the disease overview and Adenoid Cystic Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Adenoid Cystic Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Adenoid Cystic Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Adenoid Cystic Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Adenoid Cystic Carcinoma.
This segment of the Adenoid Cystic Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adenoid Cystic Carcinoma Emerging Drugs
Rivoceranib : HLB
Rivoceranib is the first small-molecule tyrosine kinase inhibitor to be approved in gastric cancer under the name Apatinib in China (December 2014). Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), the primary pathway for tumor angiogenesis. VEGFR-2 inhibition is a clinically validated approach to limit tumor growth and disease progression. Rivoceranib has been studied in over 1,000 patients worldwide and was well tolerated in clinical trials with a comparable safety profile to other TKIs. Rivoceranib is currently being studied as a monotherapy and in combination with chemotherapy and immunotherapy. Clinical studies are underway in multiple tumor types including, gastric cancer, hepatocellular carcinoma (combo w/camrelizumab), adenoid cystic carcinoma, and colorectal cancer (combo w/Lonsurf®). Orphan drug designations for rivoceranib have been granted in gastric cancer (U.S., EU, and South Korea) in adenoid cystic carcinoma (U.S.), and hepatocellular carcinoma (U.S.).
Osugacestat : Ayala Pharmaceuticals
Ayala Pharmaceuticals investigational lead candidate (AL-101) is a novel, injectable, potent and selective small molecule gamma secretase inhibitor (GSI). AL101 is currently being studied in 2 ongoing Phase 2 trials. Our ACCURACY trial for the treatment of patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC), and our Phase 2 TENACITY trial for the treatment of patients with recurrent/metastatic triple negative breast cancer (R/M TNBC). The US Food and Drug Administration (FDA) granted Orphan Drug Designation and Fast Track Designation to AL101 for the potential treatment of ACC.
Pembrolizumab : Merck & Co
Pembrolizumab is a fully humanized immunoglobulin G4/κ anti-PD-1 monoclonal antibody. Pembrolizumab has demonstrated robust antitumor activity and a favorable safety profile in multiple tumor types and is currently approved in >60 countries for 1 or more advanced malignancies, including in the United States for recurrent or metastatic head and neck squamous cell carcinoma that progressed on or after platinum-containing chemotherapy.
Further product details are provided in the report……..
This segment of the report provides insights about the different Adenoid Cystic Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Adenoid Cystic Carcinoma
There are approx. 5+ key companies which are developing the therapies for Adenoid Cystic Carcinoma. The companies which have their Adenoid Cystic Carcinoma drug candidates in the most advanced stage, i.e. phase II include, Elevar Therapeutics.
Phases
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Route of Administration
Adenoid Cystic Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Molecule Type
Products have been categorized under various Molecule types such as
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Adenoid Cystic Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adenoid Cystic Carcinoma drugs.
Current Scenario and Emerging Therapies:
Introduction
Executive Summary
Adenoid Cystic Carcinoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
Adenoid Cystic Carcinoma– DelveInsight’s Analytical Perspective
Late Stage Products (Pre-Registration)
Drug name : Company name
Drug profiles in the detailed report…..
Last Stage Products (Phase III)
Drug name : Company name
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Adenoid Cystic Carcinoma Key Companies
Adenoid Cystic Carcinoma Key Products
Adenoid Cystic Carcinoma - Unmet Needs
Adenoid Cystic Carcinoma - Market Drivers and Barriers
Adenoid Cystic Carcinoma - Future Perspectives and Conclusion
Adenoid Cystic Carcinoma Analyst Views
Adenoid Cystic Carcinoma Key Companies
Appendix
List of Table
Table 1: Total Products for Adenoid Cystic Carcinoma
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Adenoid Cystic Carcinoma
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• AL101
• CV8102
• Rivoceranib
• 9-ING-41
• Pembrolizumab
